This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Guotai Haitong Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
In a report released yesterday, from Guotai Haitong maintained a Buy rating on Wuxi Biologics (Cayman), with a price target of HK$54.49.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wuxi Biologics (Cayman) has an analyst consensus of Strong Buy, with a price target consensus of HK$46.00.
The company has a one-year high of HK$44.00 and a one-year low of HK$16.20. Currently, Wuxi Biologics (Cayman) has an average volume of 37.27M.
Read More on WXIBF:
Disclaimer & DisclosureReport an Issue
- WuXi Biologics: Robust Backlog, High-Margin Growth Drivers, and Capacity Expansion Underpin Buy Rating
- Wuxi Biologics Grants 25.6 Million Restricted Shares Under Incentive Scheme
- WuXi Biologics Schedules Briefings on 2025 Annual Results for Global Investors
- Wuxi Biologics Delivers Strong 2025 Profit Growth as Project Portfolio Expands
- WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
